Alcoi archaeological Museum. 1993 report of activities.

S'hi resumeix l'activitat realitzada al Museu durant l'any 1993 i es descriuen els diferents nivells d'actuació: administració i gestió, difusió. conservació i investigació.In this report we give an abridged account of the activities carried out at the Museum during the year 1993, stanting its diferent levels of action, that is, Administration and Management. Publications and Knowledge spreading, preservation and Research.Se resume la actividad realizada en el Museo durante el año 1993, describiéndose sus diferentes niveles de actuación: Administración y Gestión, la Difusión. Conservación e Investigación

Alcoi archaeological Museum. 2000 report of activities.

Es resumeix l' activitar realitzada durant l' any 2000 i es descriuen els diferentes nivells d' actuació: administració i gestió, difusió. conservació i investigació. Paraules clau: Activitat 2000. Visitans, Exposicions, Investigació, Museu Arqueológic Municipal d' Alcoi.In this report we give un abridged account of the activities carriecl out at the Museum during the year 2000, stanting its diferent levels of action, that is. Administration and Management. Publications and Knowledge spreading, preservation and research. Key Words: Activities 2000 . Visitors. Exhibitions. Research. The Arqueological Museum of Alcoi (province of Alicante).Se resume la actividad realizada en el Museo durante el año 2000, describiéndose sus diferentes niveles de actuación: Administración y Gestión, la Difusión e Investigación. Palabras claves: Actividades 2000; Visitantes. Exposiciones. Investigación, Museo Arqueológico Municipal de Alcoi (Alicante)

Museu Arqueològic Municipal d'Alcoi Camil Visedo i Moltó.

Es resumeix l’activitat realitzada al Museu durant l’any 1996 i es descriuen els diferents nivells d’actuació: administració i gestió, difusió, conservació i investigació

Contribucion al conocimiento de la flora del Sistema Iberico Septentrional

Se aporta un catálogo florístico de 313 táxones seleccionados procedentes de algunas de las sierras septentrionales del Sistema Ibérico aragonés: Sierras de Villarroya, Vicort, Cucalón y Retuerta, Monte de Herrera, la Modorra de Bádenas y Baños de Segura. La visita a algunas de las localidades clásicas de ASSO, ha permitido confirmar numerosas citas de las que aparecen en su Synopsis stirpium indigenarum Aragoniae (1779), así como establecer algunas sinonimias. En el aspecto nomenclatural se propone una nueva combinación: Androsace elongata L. subsp. breistrofferi (Charpin & Greuter) J . Molero & JM. Montserrat, comb. nova. En el aspecto corológico, una lista, que no pretende ser exahustiva, sobre novedades para la Flora aragonesa y otras especies escasamente citadas que incluye: Paronychia rouyana, Suene scabriflora, Sisymbrium macroloma, Hutera hispida, Saxifraga losae var. camarae, Rosa arvensis, Aphanes cornucopioides, Lathyrus cirrhosus, Trifolium retusum, Trifolium gemellum, Seseli cantabricum, Daucus durieua, Anthemis alpestris fma. ligulata , Hieracium castellanum, Festuca capillifolia , Avenula pubescens, Carex tomentosa, etc

La Práctica de la meditación y la atención plena: técnicas milenarias para padres del siglo XXI

A Mindfulness-Based training for parents of children with severe mental disorders is presented. This program was developed and tested in a specialized unit of the Public Mental Health Service of the Canary Islands. 18 mothers participated in a nonramdomize clinical trial with control group. Participants in the training showed a decrease in depression and stress scores and improvement in the relationship with their children

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.

BACKGROUND: Proliferative diabetic retinopathy (PDR) is a complication of diabetic retinopathy that can cause blindness. Although panretinal photocoagulation (PRP) is the treatment of choice for PDR, it has secondary effects that can affect vision. An alternative treatment such as anti-vascular endothelial growth factor (anti-VEGF), which produces an inhibition of vascular proliferation, could improve the vision of people with PDR. OBJECTIVES: To assess the effectiveness and safety of anti-VEGFs for PDR. SEARCH METHODS: We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 3), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to April 2014), EMBASE (January 1980 to April 2014), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 28 April 2014. SELECTION CRITERIA: We included randomised controlled trials (RCTs) comparing anti-VEGFs to another active treatment, sham treatment or no treatment for people with PDR. We also included studies that assessed the combination of anti-VEGFs with other treatments. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion, extracted data and assessed risk of bias for all included trials. We calculated the risk ratio (RR) or the mean difference (MD), and 95% confidence intervals (CI). MAIN RESULTS: We included 18 RCTs with 1005 participants (1131 eyes) of whom 57% were men. The median number of participants per RCT was 40 (range 15 to 261). The studies took place in Asia (three studies), Europe (two studies), the Middle East (seven studies), North America (three studies) and South America (three studies). Eight RCTs recruited people eligible for PRP, nine RCTs enrolled people with diabetes requiring vitrectomy and one RCT recruited people undergoing cataract surgery. The median follow-up was six months (range one to 12 months). Seven studies were at high risk of bias and the remainder were unclear risk of bias in one or more domains.Very low quality evidence from one study of 61 people showed that people treated with bevacizumab and PRP were less likely to lose 3 or more lines of visual acuity at 12 months compared with people treated with PRP alone (RR 0.19, 95% CI 0.05 to 0.81). People treated with anti-VEGF had an increased chance of gaining 3 or more lines of visual acuity but the effect was imprecise and compatible with no effect or being less likely to gain vision (RR 6.78, 95% CI 0.37 to 125.95). No other study reported these two outcomes. On average, people treated with anti-VEGF (bevacizumab, pegaptanib or ranibizumab) had better visual acuity at 12 months compared with people not receiving anti-VEGF (MD -0.07 logMAR, 95% CI -0.12 to -0.02; 5 RCTs, 373 participants, low quality evidence). There was some evidence to suggest a regression of PDR with smaller leakage on fluorescein angiography but it was difficult to estimate a pooled result from the two trials reporting this outcome. People receiving anti-VEGF were less likely to have vitreous or pre-retinal haemorrhage at 12 months (RR 0.32, 95% CI 0.16 to 0.65; 3 RCTs, 342 participants, low quality evidence). No study reported on fluorescein leakage or quality of life.All of the nine trials of anti-VEGF before or during vitrectomy investigated bevacizumab; most studies investigated bevacizumab before vitrectomy, one study investigated bevacizumab during surgery.People treated with bevacizumab and vitrectomy were less likely to lose 3 or more lines of visual acuity at 12 months compared with people given vitrectomy alone but the effect was imprecise and compatible with no effect or being more likely to lose vision (RR 0.49, 95% CI 0.08 to 3.14; 3 RCTs, 94 participants, low quality evidence). People treated with bevacizumab were more likely to gain 3 or more lines of visual acuity (RR 1.62, 95% CI 1.20 to 2.17; 3 RCTs, 94 participants, low quality evidence). On average, people treated with bevacizumab had better visual acuity at 12 months compared with people not receiving bevacizumab but there was uncertainty in the estimate (the CIs included 0; i.e. were compatible with no effect, and there was considerable inconsistency between studies; MD -0.24 logMAR, 95% CI -0.50 to 0.01; 6 RCTs, 335 participants, I(2) = 67%; low quality evidence). People receiving bevacizumab were less likely to have vitreous or pre-retinal haemorrhage at 12 months (RR 0.30, 95% CI 0.18 to 0.52; 7 RCTs, 393 participants, low quality evidence). No study reported on quality of life.Reasons for downgrading the quality of the evidence included risk of bias in included studies, imprecision of the estimates, inconsistency of effect estimates and indirectness (few studies reported at 12 months).Adverse effects were rarely reported and there was no evidence for any increased risk with anti-VEGF but given the relatively few studies that reported these, and the low event rate, the power of the analysis to detect any differences was low. AUTHORS' CONCLUSIONS: There was very low or low quality evidence from RCTs for the efficacy and safety of anti-VEGF agents when used to treat PDR over and above current standard treatments. However, the results suggest that anti-VEGFs can reduce the risk of intraocular bleeding in people with PDR. Further carefully designed clinical trials should be able to improve this evidence

Differential diagnosis between Parkinson's disease and essential tremor using the smartphone's accelerometer

Background: The differential diagnosis between patients with essential tremor (ET) and those with Parkinson's disease (PD) whose main manifestation is tremor may be difficult unless using complex neuroimaging techniques such as 123I-FP-CIT SPECT. We considered that using smartphone's accelerometer to stablish a diagnostic test based on time-frequency differences between PD an ET could support the clinical diagnosis. Methods: The study was carried out in 17 patients with PD, 16 patients with ET, 12 healthy volunteers and 7 patients with tremor of undecided diagnosis (TUD), who were re-evaluated one year after the first visit to reach the definite diagnosis. The smartphone was placed over the hand dorsum to record epochs of 30 s at rest and 30 s during arm stretching. We generated frequency power spectra and calculated receiver operating characteristics curves (ROC) curves of total spectral power, to establish a threshold to separate subjects with and without tremor. In patients with PD and ET, we found that the ROC curve of relative energy was the feature discriminating better between the two groups. This threshold was then used to classify the TUD patients. Results: We could correctly classify 49 out of 52 subjects in the category with/without tremor (97.96% sensitivity and 83.3% specificity) and 27 out of 32 patients in the category PD/ET (84.38% discrimination accuracy). Among TUD patients, 2 of 2 PD and 2 of 4 ET were correctly classified, and one patient having PD plus ET was classified as PD. Conclusions: Based on the analysis of smartphone accelerometer recordings, we found several kinematic features in the analysis of tremor that distinguished first between healthy subjects and patients and, ultimately, between PD and ET patients. The proposed method can give immediate results for the clinician to gain valuable information for the diagnosis of tremor. This can be useful in environments where more sophisticated diagnostic techniques are unavailable

Propiedades psicométricas de la versión española de la Philadelphia Mindfulness Scale

Introducción La Philadelphia Mindfulness Scale (PHLMS) es un cuestionario breve que evalúa 2 componentes clave de la atención plena: la conciencia en el momento presente y la aceptación. El presente estudio evalúa las propiedades psicométricas de la versión española de la PHLMS tanto en una muestra control de estudiantes universitarios como en población con patología psiquiátrica. Material y métodos Se administró la versión española de la PHLMS a 395 voluntarios (256 con patología psiquiátrica y 139 estudiantes). Resultados El análisis factorial exploratorio de la versión española de la PHLMS apoya la solución bifactorial de la versión original con una varianza explicada del 44,02%. La escala presentó una adecuada fiabilidad (α de Cronbach de 0,81 a 0,86). La PHLMS mostró una adecuada validez convergente con los otros cuestionarios de atención plena y aceptación y una validez divergente de la clínica depresiva y ansiosa comparable a la de la versión original. Conclusiones La versión española de la PHLMS presenta adecuadas propiedades psicométricas y puede ser utilizada para medir 2 componentes constituyentes de la atención plena -i.e. conciencia y aceptación- tanto en el ámbito clínico como en investigació